Titlebook: Antithrombotics; Andrew C. G. Uprichard (Vice President),Kim P. Gal Book 1999 Springer-Verlag Berlin Heidelberg 1999 Antithrombin.Arzneimi

起來了

Incise

Platelet Membrane Receptors and Signalling Pathways: New Therapeutic Targets,In the most severe cases, this leads to myocardial infarction or stroke, two of the major causes of death in the Western world. The platelet, therefore, is a major target for therapeutic intervention in the prevention of thrombotic disease.

Arthritis

Low Molecular Weight Heparin,n and treatment of venous thromboembolism. The low molecular weight heparins have also been used in clinical trials for the prevention and treatment of arterial thrombosis. In this chapter, we review the problems related to the use of unfractioned heparin, compare the low molecular weight heparins w

Palpate

Inhibitors of Factor Xa,o activate factors V, VIII and XI. Recruitment of these additional factors begins the “augmentation stage” which can provide large amounts of additional thrombin that plays a dominant role in subsequent thrombus formation. In both the classical coagulation cascade and the more current tissue factor

發(fā)炎

Inhibitors of Tissue Factor/Factor VIIa, of additional thrombin and, thereby, fibrin. Although the TF/VIIa complex is not directly responsible for the production of all of the thrombin needed to form a complete thrombus, it plays the crucial role of initiating the process.

我不怕犧牲

Natural Anticoagulants and Their Pathways, exposure of negatively charged phospholipids. These clotting reactions are offset by natural anticoagulant mechanisms, the most important of which are thought to include the tissue factor pathway inhibitor (Chap. 15), antithrombin-heparin (Chap. 9) and the protein C anticoagulant pathway (depicted

nostrum

惡臭